By Gabriel Paijo 
A landmark study led by researchers at Nanyang Technological University, Singapore (NTU Singapore) has revealed that blockages in the brain’s waste removal system, visible through routine imaging, may serve as one of the earliest warning signs of Alzheimer’s disease. The research suggests that these "clogged drains"—formally known as enlarged perivascular spaces (ePVS)—manifest well before the onset of clinical dementia symptoms, offering a potential window for early intervention that was previously difficult to identify without invasive or expensive testing.
The study, conducted at NTU’s Lee Kong Chian School of Medicine (LKCMedicine), provides a new perspective on the pathophysiology of neurodegenerative diseases. By identifying these structural anomalies on standard Magnetic Resonance Imaging (MRI) scans, clinicians may soon be able to screen for Alzheimer’s risk during routine check-ups for cognitive decline, bypassing the need for high-cost positron emission tomography (PET) scans or painful lumbar punctures.
The Science of Brain Waste Clearance
To understand the significance of the findings, it is essential to examine the glymphatic system, the brain’s specialized waste-clearance pathway. While the rest of the body utilizes the lymphatic system to remove cellular debris, the brain relies on perivascular spaces—small, fluid-filled channels surrounding the blood vessels—to flush out toxic metabolic byproducts.
Among the most dangerous of these byproducts are beta-amyloid and tau proteins. In a healthy brain, these proteins are efficiently cleared through the perivascular channels. However, in individuals progressing toward Alzheimer’s, these channels can become "clogged" or less efficient. This inefficiency causes the spaces to dilate or enlarge, making them visible on an MRI.
"Since these brain anomalies can be visually identified on routine MRI scans performed to evaluate cognitive decline, identifying them could complement existing methods to detect Alzheimer’s earlier, without having to do and pay for additional tests," explained Associate Professor Nagaendran Kandiah, the study’s lead author and Director of the Dementia Research Centre (Singapore) at LKCMedicine.
Bridging the Gap in Asian-Centric Neurobiology
One of the most critical aspects of the NTU study is its focus on Asian populations. Historically, the vast majority of Alzheimer’s research has been conducted on Caucasian cohorts in North America and Europe. This geographic bias has created a significant gap in medical understanding, as genetic and environmental factors vary greatly across different ethnic groups.
Research has increasingly shown that dementia does not manifest uniformly across the globe. For instance, the apolipoprotein E4 (APOE4) gene is a well-known major risk factor for Alzheimer’s. In Caucasian populations, this gene is present in approximately 50 to 60 percent of dementia patients. However, among Singaporean patients, the prevalence of APOE4 is significantly lower, appearing in less than 20 percent of cases.
The NTU team addressed this disparity by examining a diverse group of nearly 1,000 participants in Singapore. The cohort included individuals of Chinese, Malay, and Indian descent, reflecting the multi-ethnic fabric of the region. By focusing on this demographic, the researchers ensured that their findings are applicable to the rapidly aging populations of Asia, where the burden of dementia is expected to rise sharply in the coming decades.
Methodology and Comparative Analysis
The study involved a rigorous comparison between participants with healthy cognitive function and those experiencing Mild Cognitive Impairment (MCI). MCI is often considered a transitional stage between normal aging and the onset of dementia, characterized by noticeable lapses in memory or thinking speed that do not yet interfere significantly with daily life.
The researchers analyzed MRI scans of nearly 350 cognitively healthy individuals and compared them with those of participants showing signs of early decline. The results were stark: those with MCI were significantly more likely to exhibit enlarged perivascular spaces.
To validate the link between these "clogged drains" and the biological hallmarks of Alzheimer’s, the team also measured seven specific biochemical markers in the participants’ blood. These markers included levels of beta-amyloid and tau proteins, as well as neurofilament light chain (NfL), which indicates damage to nerve cells.
The data revealed a powerful correlation. Enlarged perivascular spaces were strongly associated with four of the seven blood-based biomarkers. Specifically, individuals with visible blockages in their brain’s drainage system showed higher levels of amyloid plaques and tau tangles.
Crucially, the study compared ePVS with white matter damage—a common marker of vascular health in the brain that is already widely used by doctors to assess dementia risk. The researchers found that while white matter damage is a useful indicator, the connection between Alzheimer’s-specific biochemicals and enlarged perivascular spaces was actually stronger in patients with MCI. This suggests that ePVS may be a more sensitive and specific marker for the earliest stages of Alzheimer’s than traditional metrics.
Clinical Implications for Early Intervention
The ability to detect Alzheimer’s through routine MRI scans has profound implications for the future of geriatric medicine. Justin Ong, a fifth-year medical student at LKCMedicine and the study’s first author, emphasized that time is the most valuable asset in treating neurodegeneration.
"Identifying Alzheimer’s sooner gives doctors more time to intervene and potentially slow the progression of symptoms such as memory loss, reduced thinking speed, and mood changes," Ong noted.
While there is currently no cure for Alzheimer’s, early diagnosis allows for the implementation of lifestyle modifications—such as specialized diets, cognitive exercises, and cardiovascular management—that have been shown to delay the onset of severe symptoms. Furthermore, as new disease-modifying therapies emerge, identifying patients in the "pre-symptomatic" or early MCI stage will be vital for the success of these treatments.
Expert Reactions and the Interplay of Diseases
The medical community has reacted with optimism to the NTU findings. Dr. Rachel Cheong Chin Yee, a Senior Consultant at Khoo Teck Puat Hospital’s Department of Geriatric Medicine, noted that the study sheds light on the often-overlooked role of small blood vessel health in neurodegeneration.
"These findings are significant because they suggest that brain scans showing enlarged perivascular spaces could potentially help identify people at higher risk of Alzheimer’s disease, even before symptoms appear," said Dr. Cheong, who was not involved in the research.
The study also challenges the traditional medical binary that separates "vascular dementia" (caused by blood flow issues) from "Alzheimer’s disease" (caused by protein buildup). Dr. Chong Yao Feng, a Consultant at the National University Hospital’s Division of Neurology, highlighted the "synergistic" relationship between the two.
"The study’s findings are intriguing as they demonstrate that both diseases do interact in a synergistic manner," Dr. Chong observed. He advised that when clinicians see enlarged perivascular spaces on a scan, they should not automatically assume the cause is purely vascular. Instead, they should consider it a potential red flag for underlying Alzheimer’s pathology.
Looking Ahead: The Path to Routine Screening
The NTU research team is not stopping at this discovery. The next phase of their work involves a longitudinal study, where they will track the original participants over several years. This will allow the scientists to see exactly how many individuals with enlarged perivascular spaces eventually progress to a formal diagnosis of Alzheimer’s dementia.
If the longitudinal data confirms that ePVS is a reliable predictor of future decline, it could lead to a global shift in how MRIs are read. Radiologists might soon include a specific assessment of the perivascular spaces in their reports, providing a low-cost, non-invasive screening tool for millions of aging adults.
As the global population continues to age, the socio-economic burden of Alzheimer’s is projected to become one of the greatest challenges for healthcare systems worldwide. Breakthroughs like the one at NTU Singapore offer a glimmer of hope, shifting the focus from managing late-stage symptoms to identifying and treating the disease at its very roots. By fixing the "plumbing" of the brain or at least identifying when the drains are blocked, medical science takes a significant step toward a future where Alzheimer’s is no longer an inevitable conclusion of aging.
